Read the full article by MIT about MBI HERE
|
|
|
|
|
|
|
|
|
|
|

II Workshop do Consórcio Cure Group 4

The most important highlight of the Consortium’s second in-person Workshop is the announcement that the group’s progress will allow for the planning of two clinical trials, to be initiated in the next 6 to 8 months.
 
There will be three clinical trials: the first focuses on personalized treatment with immunotherapy. The personalized adoptive cell therapy approach uses the patient’s genetic material—RNA derived from their own tumor—in dendritic cells, which are the true generals of the immune system and which instruct T cells on what to attack.
 
These cells are used both as a vaccine and as a platform to expand numerous activated T cells against the patient’s own tumor. In addition, this first trial will include what is called immune checkpoint blockade. Checkpoint blockade prevents the T cells we are infusing from becoming exhausted or deactivated when they reach the tumor.
 
As a result, they persist, expand, and remain in a much stronger activated state, leading to better elimination of the tumor. The second study is an RNA nanoparticle vaccine. By now, everyone is familiar with RNA vaccines due to COVID-19. These vaccines use mRNA packaged in a carrier (liposome) to stimulate an immune response. The approach involves using custom RNA extracted from the patient’s own tumor, but this time, the liposome can deliver the RNA directly to immune cells in the body.
 
The third study combines elements of the first two studies. The researchers call this third treatment strategy precision adoptive cell therapy. It uses a computer algorithm with predictive capabilities—Open Reading Frame Antigen Analysis (ORAN).
 
This allows the patient’s specific immune system to be studied, along with the genes expressed in that patient’s tumor, and then compared with proteins normally expressed in the human body. With this, it is hoped that it will be possible to identify, in each tumor, the real and unique components that the immune system of each patient could actually recognize as foreign and to develop an RNA-based vaccine to attack these tumor-specific antigens —a leap from personalized immunotherapy to precision immunotherapy.
 
You can learn more about the clinical trials in the interview with Dr. Duane Mitchell. Link

Compartilhe